Department of Radiation Oncology, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. j.bussink@ rther.umcn.nl
Nat Rev Clin Oncol. 2011 Jan 25;8(4):233-42. doi: 10.1038/nrclinonc.2010.218.
PET imaging has evolved as an indispensible tool for staging in oncology. Multiple quantitative measurements can be performed, enabling the effects of treatment to be monitored before changes are detectable with the use of conventional imaging modalities. PET tracers are available to visualize and quantify the most important mechanisms of resistance to radiotherapy and chemoradiotherapy. Reproducibility of these tracers depends on the particular tracer and the underlying biology of the process that is being investigated. PET enables clinicians to select patients for intensified treatment on the basis of resistance mechanisms taking place at the molecular level. From translational studies and randomized trials, it has become clear that appropriate patient selection can prevent unnecessary rejection of various treatment options through the observation of individual patients rather than only looking at the results of a large study population.
PET 成像是肿瘤学分期不可或缺的工具。可以进行多种定量测量，从而能够在使用常规成像方式检测到变化之前，监测治疗效果。PET 示踪剂可用于可视化和量化放疗和放化疗耐药的最重要机制。这些示踪剂的重现性取决于特定的示踪剂和正在研究的过程的基础生物学。PET 使临床医生能够根据分子水平上发生的耐药机制，为强化治疗选择患者。从转化研究和随机试验中可以清楚地看出，通过观察个体患者而不是仅观察大研究人群的结果，可以进行适当的患者选择，从而避免由于观察到个体患者的结果而不必要地拒绝各种治疗选择。
